Importantly, we further reveal that VC treatment induces tumor vascular normalization and boosts efficacy of anti-PD-L1 therapy or anti-PD-L1 combination therapy with IL-2 in vivo, provides promising strategies to enhance the combinational immunotherapy for liver cancer. The gene discussed is IL2; the disease is neoplasm.